TY - JOUR
T1 - Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia
AU - Kajiguchi, Masahiro
AU - Kondo, Takahisa
AU - Izawa, Hideo
AU - Kobayashi, Masayoshi
AU - Yamamoto, Koji
AU - Shintani, Satoshi
AU - Numaguchi, Yasushi
AU - Naoe, Tomoki
AU - Takamatsu, Junki
AU - Komori, Kimihiro
AU - Murohara, Toyoaki
PY - 2007
Y1 - 2007
N2 - Background: Therapeutic angiogenesis using cell transplantation (TACT) is a treatment strategy for no-option patients with critical limb ischemia (CLI). However, because one-third of treated patients fail to respond, the present study was an exploration of the characteristics of responders and non-responders to this treatment regimen. Methods and Results: Seven CLI patients (3 with Buerger's disease, 4 with arteriosclerosis obliterans undergoing chronic hemodialysis (ASO-HD)) were treated according to the TACT protocol (n=6: bone marrow-mononuclear cells (MNCs); n=1: peripheral blood-MNCs). Subjective symptoms (visual analog scale) and objective findings (extent of ulcer, ankle-brachial pressure index, transcutaneous oxygen pressure, thermography and angiography) were assessed. Numbers of transplanted CD34+, CD133 + and CD34+CD133+ cells were counted. Changes in circulating CD34+ and CD133+ cell numbers were also examined before and after the treatment. All responders (n=3) had Buerger's disease, and ASO-HD patients did not respond well. Among the responders, the numbers of circulating CD34+ and CD133+ cells persistently increased for 1 month after the treatment, but not in non-responders. Conclusions: The TACT regimen improved CLI in patients with Buerger's disease but not in those with ASOHD in this small study. In responders, post procedural circulating CD34+ and CD133+ cells persistently increased for 1 month (ClinicalTrials.gov Identifier: NCT00145262, TACT-NAGOYA).
AB - Background: Therapeutic angiogenesis using cell transplantation (TACT) is a treatment strategy for no-option patients with critical limb ischemia (CLI). However, because one-third of treated patients fail to respond, the present study was an exploration of the characteristics of responders and non-responders to this treatment regimen. Methods and Results: Seven CLI patients (3 with Buerger's disease, 4 with arteriosclerosis obliterans undergoing chronic hemodialysis (ASO-HD)) were treated according to the TACT protocol (n=6: bone marrow-mononuclear cells (MNCs); n=1: peripheral blood-MNCs). Subjective symptoms (visual analog scale) and objective findings (extent of ulcer, ankle-brachial pressure index, transcutaneous oxygen pressure, thermography and angiography) were assessed. Numbers of transplanted CD34+, CD133 + and CD34+CD133+ cells were counted. Changes in circulating CD34+ and CD133+ cell numbers were also examined before and after the treatment. All responders (n=3) had Buerger's disease, and ASO-HD patients did not respond well. Among the responders, the numbers of circulating CD34+ and CD133+ cells persistently increased for 1 month after the treatment, but not in non-responders. Conclusions: The TACT regimen improved CLI in patients with Buerger's disease but not in those with ASOHD in this small study. In responders, post procedural circulating CD34+ and CD133+ cells persistently increased for 1 month (ClinicalTrials.gov Identifier: NCT00145262, TACT-NAGOYA).
UR - http://www.scopus.com/inward/record.url?scp=33846565985&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846565985&partnerID=8YFLogxK
U2 - 10.1253/circj.71.196
DO - 10.1253/circj.71.196
M3 - Article
C2 - 17251666
AN - SCOPUS:33846565985
SN - 1346-9843
VL - 71
SP - 196
EP - 201
JO - Circulation Journal
JF - Circulation Journal
IS - 2
ER -